Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)
With the advent of antiretroviral therapy regimens in HIV positive patients, it is crucial to consider their long-term benefits to risk ratios. The responsibility of treatment in premature atherosclerosis is not clear. Thus, the aim of this study is to evaluate the impact of exposure to reverse tran...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 2006-04, Vol.185 (2), p.361-367 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 367 |
|---|---|
| container_issue | 2 |
| container_start_page | 361 |
| container_title | Atherosclerosis |
| container_volume | 185 |
| creator | Martin, Luc de Saint Vandhuick, Olivier Guillo, Philippe Bellein, Véronique Bressollette, Luc Roudaut, Nathalie Amaral, Antonio Pasquier, Elisabeth |
| description | With the advent of antiretroviral therapy regimens in HIV positive patients, it is crucial to consider their long-term benefits to risk ratios. The responsibility of treatment in premature atherosclerosis is not clear. Thus, the aim of this study is to evaluate the impact of exposure to reverse transcriptase inhibitors (nucleosidic and non-nucleosidic) and to protease inhibitors on the cardiovascular status of an entire hospital based cohort of patients.
154 patients were included. Using a linear analysis, we sought an association between the cumulative time of exposure to these three classes of antiretroviral drugs and the carotid intima-media thickness measured by ultrasonography and a cardiovascular composite score.
The study confirms premature atherosclerosis, which not only correlates with the usual risk factors, such as triglyceride level, but also with protease inhibitor exposure, especially that of lopinavir. Nevertheless as regards current drug exposure, the clinical impact was low: five clinical complications of atherosclerosis and only one out of 35 scintigraphic and ECG exercise tests warranted a coronary angiography which was negative.
These data should not lead to the rejection of protease inhibitors but should strengthen the prevention of cardiovascular diseases as an integral part of the management of HIV patients. |
| doi_str_mv | 10.1016/j.atherosclerosis.2005.06.049 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00688306v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915005003886</els_id><sourcerecordid>S0021915005003886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-ad6a31f1e3f2a8b545bb99f6f9111db511dcfbeb60852555c30266775bdaa4e43</originalsourceid><addsrcrecordid>eNqNkMFq3DAQhkVpabZpXqHoEmgOdke2JNuHHpbQZgMLLSTNVYwlmWix10aSl-zbV2aXFHLqZYYR3_8jPkKuGeQMmPy2yzE-Wz8G3S_ThbwAEDnIHHjzjqxYXTUZ4zV_T1YABcsaJuCCfAphBwC8YvVHcsEkKyvZiBU5_vZ2wDh7S9_0Urenm_snOqUjuoOlE0Zn9zFQ3Buq52HuMVpDoxssHTtqXxK59MQxEdF5G_14cB57uhTjdKRfH1LhmoY4m-PNZ_Khwz7Yq_O-JH9-_ni83WTbX3f3t-ttprlgMUMjsWQds2VXYN0KLtq2aTrZNYwx04o0dNfaVkItCiGELqGQsqpEaxC55eUluTn1PmOvJu8G9Ec1olOb9VYtbwCyrkuQB5bY7ydWJwXB2-41wEAt-tVOvdGkFv0KpEr6U_7LKT_N7WDNv_TZdwKuzwAGjX3nca9TxytXibrgIBN3d-JsMnNw1qugk3xtTfKqozKj-88v_QV5Sq9m</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Martin, Luc de Saint ; Vandhuick, Olivier ; Guillo, Philippe ; Bellein, Véronique ; Bressollette, Luc ; Roudaut, Nathalie ; Amaral, Antonio ; Pasquier, Elisabeth</creator><creatorcontrib>Martin, Luc de Saint ; Vandhuick, Olivier ; Guillo, Philippe ; Bellein, Véronique ; Bressollette, Luc ; Roudaut, Nathalie ; Amaral, Antonio ; Pasquier, Elisabeth</creatorcontrib><description>With the advent of antiretroviral therapy regimens in HIV positive patients, it is crucial to consider their long-term benefits to risk ratios. The responsibility of treatment in premature atherosclerosis is not clear. Thus, the aim of this study is to evaluate the impact of exposure to reverse transcriptase inhibitors (nucleosidic and non-nucleosidic) and to protease inhibitors on the cardiovascular status of an entire hospital based cohort of patients.
154 patients were included. Using a linear analysis, we sought an association between the cumulative time of exposure to these three classes of antiretroviral drugs and the carotid intima-media thickness measured by ultrasonography and a cardiovascular composite score.
The study confirms premature atherosclerosis, which not only correlates with the usual risk factors, such as triglyceride level, but also with protease inhibitor exposure, especially that of lopinavir. Nevertheless as regards current drug exposure, the clinical impact was low: five clinical complications of atherosclerosis and only one out of 35 scintigraphic and ECG exercise tests warranted a coronary angiography which was negative.
These data should not lead to the rejection of protease inhibitors but should strengthen the prevention of cardiovascular diseases as an integral part of the management of HIV patients.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2005.06.049</identifier><identifier>PMID: 16137695</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Adult ; Anti-Retroviral Agents ; Anti-Retroviral Agents - adverse effects ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral therapy ; Antiretroviral Therapy, Highly Active ; Antiretroviral Therapy, Highly Active - adverse effects ; Atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Atherosclerosis - etiology ; Atherosclerosis - pathology ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiology. Vascular system ; Cardiovascular disease ; Cardiovascular Diseases ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - diagnosis ; Cardiovascular system ; Carotid Artery, Common ; Carotid Artery, Common - pathology ; Cohort Studies ; HIV ; HIV Protease Inhibitors ; HIV Protease Inhibitors - adverse effects ; HIV Protease Inhibitors - therapeutic use ; HIV Seropositivity ; HIV Seropositivity - complications ; HIV Seropositivity - drug therapy ; Human health and pathology ; Humans ; Intima-media thickness ; Life Sciences ; Lipids ; Lipids - blood ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Reverse Transcriptase Inhibitors ; Reverse Transcriptase Inhibitors - adverse effects ; Reverse Transcriptase Inhibitors - therapeutic use ; Risk Factors ; Tunica Intima ; Tunica Intima - drug effects ; Tunica Intima - pathology ; Tunica Media ; Tunica Media - drug effects ; Tunica Media - pathology ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Atherosclerosis, 2006-04, Vol.185 (2), p.361-367</ispartof><rights>2005</rights><rights>2006 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-ad6a31f1e3f2a8b545bb99f6f9111db511dcfbeb60852555c30266775bdaa4e43</citedby><cites>FETCH-LOGICAL-c451t-ad6a31f1e3f2a8b545bb99f6f9111db511dcfbeb60852555c30266775bdaa4e43</cites><orcidid>0000-0002-8354-469X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.atherosclerosis.2005.06.049$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17582406$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16137695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-brest.fr/hal-00688306$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, Luc de Saint</creatorcontrib><creatorcontrib>Vandhuick, Olivier</creatorcontrib><creatorcontrib>Guillo, Philippe</creatorcontrib><creatorcontrib>Bellein, Véronique</creatorcontrib><creatorcontrib>Bressollette, Luc</creatorcontrib><creatorcontrib>Roudaut, Nathalie</creatorcontrib><creatorcontrib>Amaral, Antonio</creatorcontrib><creatorcontrib>Pasquier, Elisabeth</creatorcontrib><title>Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>With the advent of antiretroviral therapy regimens in HIV positive patients, it is crucial to consider their long-term benefits to risk ratios. The responsibility of treatment in premature atherosclerosis is not clear. Thus, the aim of this study is to evaluate the impact of exposure to reverse transcriptase inhibitors (nucleosidic and non-nucleosidic) and to protease inhibitors on the cardiovascular status of an entire hospital based cohort of patients.
154 patients were included. Using a linear analysis, we sought an association between the cumulative time of exposure to these three classes of antiretroviral drugs and the carotid intima-media thickness measured by ultrasonography and a cardiovascular composite score.
The study confirms premature atherosclerosis, which not only correlates with the usual risk factors, such as triglyceride level, but also with protease inhibitor exposure, especially that of lopinavir. Nevertheless as regards current drug exposure, the clinical impact was low: five clinical complications of atherosclerosis and only one out of 35 scintigraphic and ECG exercise tests warranted a coronary angiography which was negative.
These data should not lead to the rejection of protease inhibitors but should strengthen the prevention of cardiovascular diseases as an integral part of the management of HIV patients.</description><subject>Adult</subject><subject>Anti-Retroviral Agents</subject><subject>Anti-Retroviral Agents - adverse effects</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretroviral therapy</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Atherosclerosis - etiology</subject><subject>Atherosclerosis - pathology</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular system</subject><subject>Carotid Artery, Common</subject><subject>Carotid Artery, Common - pathology</subject><subject>Cohort Studies</subject><subject>HIV</subject><subject>HIV Protease Inhibitors</subject><subject>HIV Protease Inhibitors - adverse effects</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>HIV Seropositivity</subject><subject>HIV Seropositivity - complications</subject><subject>HIV Seropositivity - drug therapy</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Intima-media thickness</subject><subject>Life Sciences</subject><subject>Lipids</subject><subject>Lipids - blood</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Reverse Transcriptase Inhibitors</subject><subject>Reverse Transcriptase Inhibitors - adverse effects</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Risk Factors</subject><subject>Tunica Intima</subject><subject>Tunica Intima - drug effects</subject><subject>Tunica Intima - pathology</subject><subject>Tunica Media</subject><subject>Tunica Media - drug effects</subject><subject>Tunica Media - pathology</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFq3DAQhkVpabZpXqHoEmgOdke2JNuHHpbQZgMLLSTNVYwlmWix10aSl-zbV2aXFHLqZYYR3_8jPkKuGeQMmPy2yzE-Wz8G3S_ThbwAEDnIHHjzjqxYXTUZ4zV_T1YABcsaJuCCfAphBwC8YvVHcsEkKyvZiBU5_vZ2wDh7S9_0Urenm_snOqUjuoOlE0Zn9zFQ3Buq52HuMVpDoxssHTtqXxK59MQxEdF5G_14cB57uhTjdKRfH1LhmoY4m-PNZ_Khwz7Yq_O-JH9-_ni83WTbX3f3t-ttprlgMUMjsWQds2VXYN0KLtq2aTrZNYwx04o0dNfaVkItCiGELqGQsqpEaxC55eUluTn1PmOvJu8G9Ec1olOb9VYtbwCyrkuQB5bY7ydWJwXB2-41wEAt-tVOvdGkFv0KpEr6U_7LKT_N7WDNv_TZdwKuzwAGjX3nca9TxytXibrgIBN3d-JsMnNw1qugk3xtTfKqozKj-88v_QV5Sq9m</recordid><startdate>20060401</startdate><enddate>20060401</enddate><creator>Martin, Luc de Saint</creator><creator>Vandhuick, Olivier</creator><creator>Guillo, Philippe</creator><creator>Bellein, Véronique</creator><creator>Bressollette, Luc</creator><creator>Roudaut, Nathalie</creator><creator>Amaral, Antonio</creator><creator>Pasquier, Elisabeth</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-8354-469X</orcidid></search><sort><creationdate>20060401</creationdate><title>Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)</title><author>Martin, Luc de Saint ; Vandhuick, Olivier ; Guillo, Philippe ; Bellein, Véronique ; Bressollette, Luc ; Roudaut, Nathalie ; Amaral, Antonio ; Pasquier, Elisabeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-ad6a31f1e3f2a8b545bb99f6f9111db511dcfbeb60852555c30266775bdaa4e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Anti-Retroviral Agents</topic><topic>Anti-Retroviral Agents - adverse effects</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretroviral therapy</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Atherosclerosis - etiology</topic><topic>Atherosclerosis - pathology</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular system</topic><topic>Carotid Artery, Common</topic><topic>Carotid Artery, Common - pathology</topic><topic>Cohort Studies</topic><topic>HIV</topic><topic>HIV Protease Inhibitors</topic><topic>HIV Protease Inhibitors - adverse effects</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>HIV Seropositivity</topic><topic>HIV Seropositivity - complications</topic><topic>HIV Seropositivity - drug therapy</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Intima-media thickness</topic><topic>Life Sciences</topic><topic>Lipids</topic><topic>Lipids - blood</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Reverse Transcriptase Inhibitors</topic><topic>Reverse Transcriptase Inhibitors - adverse effects</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Risk Factors</topic><topic>Tunica Intima</topic><topic>Tunica Intima - drug effects</topic><topic>Tunica Intima - pathology</topic><topic>Tunica Media</topic><topic>Tunica Media - drug effects</topic><topic>Tunica Media - pathology</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, Luc de Saint</creatorcontrib><creatorcontrib>Vandhuick, Olivier</creatorcontrib><creatorcontrib>Guillo, Philippe</creatorcontrib><creatorcontrib>Bellein, Véronique</creatorcontrib><creatorcontrib>Bressollette, Luc</creatorcontrib><creatorcontrib>Roudaut, Nathalie</creatorcontrib><creatorcontrib>Amaral, Antonio</creatorcontrib><creatorcontrib>Pasquier, Elisabeth</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, Luc de Saint</au><au>Vandhuick, Olivier</au><au>Guillo, Philippe</au><au>Bellein, Véronique</au><au>Bressollette, Luc</au><au>Roudaut, Nathalie</au><au>Amaral, Antonio</au><au>Pasquier, Elisabeth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2006-04-01</date><risdate>2006</risdate><volume>185</volume><issue>2</issue><spage>361</spage><epage>367</epage><pages>361-367</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>With the advent of antiretroviral therapy regimens in HIV positive patients, it is crucial to consider their long-term benefits to risk ratios. The responsibility of treatment in premature atherosclerosis is not clear. Thus, the aim of this study is to evaluate the impact of exposure to reverse transcriptase inhibitors (nucleosidic and non-nucleosidic) and to protease inhibitors on the cardiovascular status of an entire hospital based cohort of patients.
154 patients were included. Using a linear analysis, we sought an association between the cumulative time of exposure to these three classes of antiretroviral drugs and the carotid intima-media thickness measured by ultrasonography and a cardiovascular composite score.
The study confirms premature atherosclerosis, which not only correlates with the usual risk factors, such as triglyceride level, but also with protease inhibitor exposure, especially that of lopinavir. Nevertheless as regards current drug exposure, the clinical impact was low: five clinical complications of atherosclerosis and only one out of 35 scintigraphic and ECG exercise tests warranted a coronary angiography which was negative.
These data should not lead to the rejection of protease inhibitors but should strengthen the prevention of cardiovascular diseases as an integral part of the management of HIV patients.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>16137695</pmid><doi>10.1016/j.atherosclerosis.2005.06.049</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8354-469X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 2006-04, Vol.185 (2), p.361-367 |
| issn | 0021-9150 1879-1484 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00688306v1 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Anti-Retroviral Agents Anti-Retroviral Agents - adverse effects Anti-Retroviral Agents - therapeutic use Antiretroviral therapy Antiretroviral Therapy, Highly Active Antiretroviral Therapy, Highly Active - adverse effects Atherosclerosis Atherosclerosis (general aspects, experimental research) Atherosclerosis - etiology Atherosclerosis - pathology Biological and medical sciences Blood and lymphatic vessels Blood. Blood coagulation. Reticuloendothelial system Cardiology. Vascular system Cardiovascular disease Cardiovascular Diseases Cardiovascular Diseases - complications Cardiovascular Diseases - diagnosis Cardiovascular system Carotid Artery, Common Carotid Artery, Common - pathology Cohort Studies HIV HIV Protease Inhibitors HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - therapeutic use HIV Seropositivity HIV Seropositivity - complications HIV Seropositivity - drug therapy Human health and pathology Humans Intima-media thickness Life Sciences Lipids Lipids - blood Medical sciences Middle Aged Pharmacology. Drug treatments Reverse Transcriptase Inhibitors Reverse Transcriptase Inhibitors - adverse effects Reverse Transcriptase Inhibitors - therapeutic use Risk Factors Tunica Intima Tunica Intima - drug effects Tunica Intima - pathology Tunica Media Tunica Media - drug effects Tunica Media - pathology Vasodilator agents. Cerebral vasodilators |
| title | Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A45%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Premature%20atherosclerosis%20in%20HIV%20positive%20patients%20and%20cumulated%20time%20of%20exposure%20to%20antiretroviral%20therapy%20(SHIVA%20study)&rft.jtitle=Atherosclerosis&rft.au=Martin,%20Luc%20de%20Saint&rft.date=2006-04-01&rft.volume=185&rft.issue=2&rft.spage=361&rft.epage=367&rft.pages=361-367&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2005.06.049&rft_dat=%3Celsevier_hal_p%3ES0021915005003886%3C/elsevier_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16137695&rft_els_id=S0021915005003886&rfr_iscdi=true |